{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3"},{"groupId":"OG001","value":"6.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"The percentage of participants who received RBC transfusions during the titration and evaluation periods were reported.","groups":[{"description":"Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.","id":"OG000","title":"Mircera"},{"description":"Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.","id":"OG001","title":"Darbepoetin Alfa"}],"paramType":"NUMBER","populationDescription":"ITT population.","reportingStatus":"POSTED","timeFrame":"Baseline up to Week 28","title":"Percentage of Participants With Red Blood Cell (RBC) Transfusions","type":"SECONDARY","unitOfMeasure":"percentage of participants"}